

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 57359

**Title:** COVID-19 and Information and Communication Technology in Radiation Oncology: A New Paradigm

**Reviewer's code:** 02509032

**Position:** Editor-in-Chief

**Academic degree:** BM BCh, BSc, FRCS, PhD

**Professional title:** Professor, Surgical Oncologist

**Reviewer's Country/Territory:** Norway

**Author's Country/Territory:** Spain

**Manuscript submission date:** 2020-06-04

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2020-06-04 17:19

**Reviewer performed review:** 2020-06-04 17:23

**Review time:** 1 Hour

<b>Scientific quality</b>	[ <input checked="" type="radio"/> ] Grade A: Excellent [ <input type="radio"/> ] Grade B: Very good [ <input type="radio"/> ] Grade C: Good [ <input type="radio"/> ] Grade D: Fair [ <input type="radio"/> ] Grade E: Do not publish
<b>Language quality</b>	[ <input checked="" type="radio"/> ] Grade A: Priority publishing [ <input type="radio"/> ] Grade B: Minor language polishing [ <input type="radio"/> ] Grade C: A great deal of language polishing [ <input type="radio"/> ] Grade D: Rejection
<b>Conclusion</b>	[ <input checked="" type="radio"/> ] Accept (High priority) [ <input type="radio"/> ] Accept (General priority) [ <input type="radio"/> ] Minor revision [ <input type="radio"/> ] Major revision [ <input type="radio"/> ] Rejection
<b>Re-review</b>	[ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No
<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

This is a well written and timely article on an important subject.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Oncology

**Manuscript NO:** 57359

**Title:** COVID-19 and Information and Communication Technology in Radiation Oncology: A New Paradigm

**Reviewer's code:** 04480049

**Position:** Peer Reviewer

**Academic degree:** MD, PhD

**Professional title:** Assistant Professor, Doctor

**Reviewer's Country/Territory:** Bulgaria

**Author's Country/Territory:** Spain

**Manuscript submission date:** 2020-06-04

**Reviewer chosen by:** Ya-Juan Ma

**Reviewer accepted review:** 2020-09-20 15:25

**Reviewer performed review:** 2020-09-22 09:47

**Review time:** 1 Day and 18 Hours

<b>Scientific quality</b>	[ <input checked="" type="checkbox"/> ] Grade A: Excellent [ <input type="checkbox"/> ] Grade B: Very good [ <input type="checkbox"/> ] Grade C: Good [ <input type="checkbox"/> ] Grade D: Fair [ <input type="checkbox"/> ] Grade E: Do not publish
<b>Language quality</b>	[ <input checked="" type="checkbox"/> ] Grade A: Priority publishing [ <input type="checkbox"/> ] Grade B: Minor language polishing [ <input type="checkbox"/> ] Grade C: A great deal of language polishing [ <input type="checkbox"/> ] Grade D: Rejection
<b>Conclusion</b>	[ <input type="checkbox"/> ] Accept (High priority) [ <input type="checkbox"/> ] Accept (General priority) [ <input checked="" type="checkbox"/> ] Minor revision [ <input type="checkbox"/> ] Major revision [ <input type="checkbox"/> ] Rejection
<b>Re-review</b>	[ <input checked="" type="checkbox"/> ] Yes [ <input type="checkbox"/> ] No
<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No

#### **SPECIFIC COMMENTS TO AUTHORS**

Outstanding expert opinion focusing on radiation oncology and telemedicine best practices. In fact, other specialties should definitely learn from authors' experience for the implication of eHealth under real-world clinical conditions. My comments are as follows: 1. Disclose COVID-19 and SARS-CoV-2 at first mentioning in manuscript body and abstract. 2. Make the conclusion a different section with a subheading.